A rare trigger for macrophage activation syndrome
-
Upload
shikhar-agarwal -
Category
Documents
-
view
216 -
download
1
Transcript of A rare trigger for macrophage activation syndrome
![Page 1: A rare trigger for macrophage activation syndrome](https://reader035.fdocuments.us/reader035/viewer/2022073106/57502b211a28ab877ed00b5b/html5/thumbnails/1.jpg)
Rheumatol Int (2011) 31:405–407
DOI 10.1007/s00296-009-1204-0CASE REPORT
A rare trigger for macrophage activation syndrome
Shikhar Agarwal · Jayavani Moodley · Gati Ajani Goel · Karl S. Theil · Syed S. Mahmood · Richard S. Lang
Received: 3 July 2009 / Accepted: 13 September 2009 / Published online: 16 October 2009© Springer-Verlag 2009
Abstract Macrophage activation syndrome (MAS) is adisorder characterized by increased activation of mononu-clear cells leading to phagocytosis of blood cell precursorsin the bone marrow. We describe a case of MAS triggeredby disseminated histoplasmosis occurring in a patient withStill’s disease on long-term treatment with adalimumab.
Keywords Macrophage activation syndrome · Histoplasma · Hemophagocytosis
Case report
A 21-year-old Caucasian male with a history of Still’s dis-ease diagnosed 2 years prior presented with fevers to 105°F,constitutional symptoms, headache, and migratory jointpains. He had been treated with intermittent courses ofprednisone, methotrexate, and anakinra. For the past 1 yearhe was maintained in remission on adalimumab alone.
Examination revealed an erythematous macular rash of thetrunk, marked scleral icterus, and hepatomegaly.
Laboratory data on admission were signiWcant forhematocrit 44%, white blood cell count (WBC) 5.09 £ 109/L, platelet count 76 £ 109/L, bilirubin 5.2 mg/dL, AST361 U/L, ALT 526 U/L, alkaline phosphatase 374 U/L, cre-atinine 1.01 mg/dL, erythrocyte sedimentation rate 5 mm/h,hypocomplementemia (C3 60 mg/dL, C4 10 mg/dL), Lac-tate dehydrogenase 4,807 U/L and elevated ferritin13,800 ng/mL, triglycerides 342 mg/dL, and d-dimer18,400 ng/mL. A diagnosis of MAS was considered andbone marrow (BM) aspiration and biopsy undertaken.
Hospital course was complicated by unremitting fevers,increasing dyspnea, profound pancytopenia (nadir hemato-crit 19%, WBC 3 £ 109/L, platelets 12 £ 109/L) and wors-ening liver function (peak total bilirubin 19.3 mg/dL, AST1050 U/L, ALT 530 U/L, alkaline phosphatase 470 U/L). Acomputed tomographic scan of his chest revealed diVusenodules in both lung Welds producing hazy ground glassopaciWcation. An infectious disease work-up revealed posi-tive antibody titers for Histoplasma capsulatum at 1:128 (N< 1:8) and a positive Histoplasma urinary antigen. Geneprobe analysis was positive for H. capsulatum DNA. Sub-sequent bronchoalveolar lavage demonstrated yeast forms,consistent with histoplasmosis.
MAS was conWrmed by BM aspirate (Fig. 1) and biopsy(Fig. 2), which demonstrated macrophages with hemophag-ocytosis with and without intracellular budding yeastforms, morphologically compatible with H. capsulatuminfection. The patient was treated with intravenous ampho-tericin B (4 mg/kg/day) for disseminated histoplasmosis,and subcutaneous anakinra (100 mg/day), and high dosesteroids for MAS. He demonstrated steady recovery on thisregimen and was discharged home in stable condition3 weeks later.
S. Agarwal · J. Moodley · G. Ajani GoelDepartment of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USAe-mail: [email protected]
K. S. TheilDepartment of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA
S. S. MahmoodSchool of Medicine, Case Western Reserve University, Cleveland, OH, USA
R. S. Lang (&)Department of Preventive Medicine, Cleveland Clinic Foundation, Desk A-11, 9500 Euclid Avenue, Cleveland, OH 44195, USAe-mail: [email protected]
123
![Page 2: A rare trigger for macrophage activation syndrome](https://reader035.fdocuments.us/reader035/viewer/2022073106/57502b211a28ab877ed00b5b/html5/thumbnails/2.jpg)
406 Rheumatol Int (2011) 31:405–407
Discussion
MAS or hemophagocytic syndrome is a severe and poten-tially life-threatening complication of systemic juvenilerheumatoid arthritis, systemic lupus erythematosus (SLE),and other rheumatic diseases [1]. MAS is believed to be animmunologically mediated reactive disorder of mononu-clear cells, characterized by exaggerated activation of
macrophages leading to phagocytosis of erythrocyticprecursors (hemophagocytosis) [2] and multiorgan dysfunc-tion. Although MAS is considered a rare complication ofStill’s disease, the syndrome may be under-diagnosedbecause of failure to recognize the clinical constellation, andthe necessity of BM examination to make the diagnosis [2].
Recognition of MAS is often challenging because it maymimic the clinical features of the patient’s underlying diseaseor be confused with an infectious complication. Non-remittinghigh fevers, hepatosplenomegaly, lymphadenopathy, and cen-tral nervous dysfunction [3] are characteristic features associ-ated with MAS. Laboratory features include pancytopenia,coagulopathy, hypoWbrinogenemia, elevated liver enzymes,and hypertriglyceridemia [4]. The characteristic Wndingsinclude high levels of lactate dehydrogenase and markedlyelevated ferritin derived from the phagocytic macrophages.
Although the cause of MAS remains unknown, triggerssuch as infections (e.g., Epstein-Barr virus, adenovirus,dengue, leishmania, histoplasma [5]), and drugs (e.g., aspi-rin, phenytoin, methotrexate, inXiximab, etanercept) havebeen implicated. Less than ten reported cases of MAS inthe setting of disseminated histoplasmosis [5] have beendescribed, the majority of which occurred in HIV-infectedindividuals. Prompt diagnosis of MAS is essential becauseearly treatment favors a better outcome. MAS is usuallytreated by eradication of triggers, immunosuppressive ther-apy and/or administration of intravenous immune globu-lins. Despite treatment, MAS is associated with a highmortality rate (approximately 50%) [6].
Fig. 1 Macrophages with hemophagocytosis and rare small intracellular budding yeast compatible with Histoplasma capsulatum (arrows) were iden-tiWed in bone marrow aspirate smear (Wright–Giemsa)
Fig. 2 Left panel bone marrow biopsy showed macrophages withhemophagocytosis (blue arrows) (Hematoxylin–eosin stain). Rightpanel small budding yeast compatible with Histoplasma capsulatum(black arrows) were present (Gomori methamine silver stain)
123
![Page 3: A rare trigger for macrophage activation syndrome](https://reader035.fdocuments.us/reader035/viewer/2022073106/57502b211a28ab877ed00b5b/html5/thumbnails/3.jpg)
Rheumatol Int (2011) 31:405–407 407
Conclusions
• MAS or hemophagocytic syndrome is a rare complica-tion seen with rheumatic diseases, especially rheumaticdiseases.
• MAS is an immunologically mediated reactive disorderof mononuclear cells, characterized by exaggerated acti-vation of macrophages leading to phagocytosis of bloodcell precursors.
• MAS is characterized by multiorgan dysfunction withsymptoms mimicking a Still’s Xare. Subtle diVerencesinclude non-remitting high fevers, hepatosplenomegaly,lymphadenopathy and central nervous dysfunction withlaboratory features including pancytopenia, coagulopa-thy, hypertriglyceridemia, and hyperferrritinemia.
• MAS is characteristically associated with an identiWabletrigger like drugs or infection.
• Histoplasma capsulatum has been identiWed as a raretrigger for MAS.
References
1. Kuzmanova SI (2005) The macrophage activation syndrome: a newentity, a potentially fatal complication of rheumatic disorders. FoliaMed (Plovdiv) 47(1):21–25
2. Ravelli A (2002) Macrophage activation syndrome. Curr OpinRheumatol 14(5):548–552
3. Rumbach L, Berger E, Tatu L et al (1997) Transient multiple cranialnerve involvement as a Wrst sign of macrophage activation syn-drome. J Neurol Neurosurg Psychiatry 62(3):292–293
4. Lambotte O, Cacoub P, Costedoat N, Le Moel G, Amoura Z, PietteJC (2003) High ferritin and low glycosylated ferritin may also be amarker of excessive macrophage activation. J Rheumatol30(5):1027–1028
5. Sanchez A, Celaya AK, Victorio A (2007) Histoplasmosis-associat-ed hemophagocytic syndrome: a case report. AIDS Read17(10):496–499
6. Pinto L, Kagalwala F, Singh S, Balakrishnan C, Prabhu SV,Khodaiji S (2007) Macrophage activation syndrome: experiencefrom a tertiary referral centre. J Assoc Physicians India 55:185–187
123